The European Commission approves AstraZeneca's Enhertu for a new breast cancer indication while also expanding Imfinzi label ...

Daiichi Sankyo Company, Limited leads in ADC tech with Enhertu, strong partnerships, revenue growth, and global market leadership. Click to know more on why DSNKY is a Buy.

EU approves expanded use of ABBV's Rinvoq and AZN's Imfinzi and Enhertu. NVS set to invest $23B to boost U.S. manufacturing.

AstraZeneca and Daiichi Sankyo have claimed approval from the European Commission for their TROP2-directed antibody-drug ...

TOKYO, Japan & MUNICH, Germany I April 08, 2025 I DATROWAY® (datopotamab deruxtecan) has been approved in the European Union (EU) for the treatment of ...

Two impressive studies in lung cancer and another in breast ... which could extend the reach of antibody-drug conjugate (ADC) Enhertu in breast cancer with even lower levels of biomarker HER2.

AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. | ...

The FDA cleared the firm this week to begin a Phase I study of ALX2004 in EGFR-expressing solid tumors, which could start in a few months.

An analysis of exhaled breath, using an electronic nose, demonstrates potential for accurately detecting lung cancer in ...